Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance

NCT07178457 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

84

Enrollment

OTHER

Sponsor class

Conditions

Cutaneous T Cell Lymphoma (CTCL)
Brentuximab Vedotin

Interventions

DRUG: Brentuximab Vedotin (Bv)
DRUG: Placebo

Sponsor

Assistance Publique - Hôpitaux de Paris